3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
27
Cisplatin
17
Nivolumab
14
Cyclophosphamide
14
Carboplatin
13
Radiation
12
Paclitaxel
12
Doxorubicin
11
Radiotherapy
10
Radiotherapy, Intensity-Modulated
9
Cytarabine
9
Vincristine
8
Magnetic Resonance Spectroscopy
8
Docetaxel
8
Bevacizumab
8
Radiosurgery
7
Leucovorin
7
Fluorouracil
7
Etoposide
7
Specimen Handling
6
Prednisone
6
Pemetrexed
6
Irinotecan
6
Injections
6
Gemcitabine
6
Dexamethasone
6
venetoclax
5
tislelizumab
5
fludarabine
5
enzalutamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diphenhydramine
×
30 days
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts